Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer

Hashimoto, Akinori; Takada, Kohichi; Horiguchi, Hyogo; Sato, Tsutomu; Iyama, Satoshi; Murase, Kazuyuki; Kamihara, Yusuke; Ono, Kaoru; Tatekoshi, Ayumi; Hayashi, Tsuyoshi; Miyanishi, Koji; Sato, Yasushi; Furuhata, Tomohisa; Kobune, Masayoshi; Takimoto, Rishu; Hirata, Koichi; Kato, Junji

doi:10.1159/000363100

Cited by 5 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TopII inhibitors cause chromosomal translocations that most often involve the KMT2A genes on chromosome 11q23, RUNX1 on 21q22 and PML/RARA. The development of leukemia has a shorter period ranging from 1 to 3 years and is almost never preceded by a MDS (20,(26)(27)(28).…”

Section: Therapy-related Amlmentioning

confidence: 99%

Secondary Acute Myeloid Leukemia: Pathogenesis and Treatment

et al. 2022

View full text Add to dashboard Cite

Secondary acute myeloid leukemia includes acute myeloid leukemia that arises either from a previous myeloid hematologic disease such as myelodysplastic syndrome, chronic myeloproliferative syndrome, or myelodysplastic/myeloproliferative overlap syndromes or from a previous chemotherapy or radiotherapy performed for another disease. Secondary acute myeloid leukemia is characterized by a worse prognosis than its de novo counterparts, with a 5-year overall survival of < 30% despite an advanced insight into pathogenesis and new available treatments. The best therapeutic strategy is to achieve complete remission with a negative minimal residual disease followed by hematopoietic stem cell transplantation; however, advanced age of patients at diagnosis, multiple comorbidities, and lower rate of complete remission makes these approaches available only for a Note to the Reader: This chapter is part of the book Leukemia (ISBN: 978-0-6453320-7-0), scheduled for publication in September 2022. The book is being published by Exon Publications,

show abstract

Section: Therapy-related Amlmentioning

confidence: 99%

Secondary Acute Myeloid Leukemia: Pathogenesis and Treatment

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The TOP II inhibitor induces t-AML with balanced translocations that generally arise within 3 years. It is often associated with mixed lymphocytic leukemia (MLL), runt-related transcription factor 1 (RUNX1), and retinoic acid receptor alpha (RARA) loci at 11q23, 21q22, and 17q21, respectively [ 25 , 26 ].…”

Section: Etiology Of Therapy-related Myeloid Neoplasmsmentioning

confidence: 99%

Genetic Pathway in the Pathogenesis of Therapy-Related Myeloid Neoplasms: A Literature Review

2020

View full text Add to dashboard Cite

Therapy-related myeloid neoplasms are a life-threatening and often fatal complication, associated with poor prognosis outcomes and with high-risk unfavorable cytogenetic abnormalities including complex karyotype. They occur after the treatment of primary malignancies using chemotherapy and/or radiation therapy. Such therapy is not specific to cancer cells, and also damages the deoxyribonucleic acid (DNA) of normal cells, resulting in unbalanced and balanced translocations. There are eight genetic pathways, whose details are summarized in this review, depending on the cytogenetic abnormalities induced. This abnormality is the major contributor to the development of therapy-related myeloid neoplasms. The etiology of these neoplasms depends on the complex interaction between the nature and dose of the cytotoxic agent, the environment, and the presence of subsequent inherited mutations. This review aims to elaborate upon recent knowledge regarding the etiology, pathogenesis, and genetic pathways of therapy-related myeloid neoplasms. A deeper understanding of their etiology would aid physicians in more careful monitoring of patients during or after cytotoxic therapy for hematological malignancy. Ultimately, this knowledge could influence initial treatment strategies, with the aim of reducing both the incidence and serious complications of neoplasms. Therefore, early detection of DNA lesions is vital. The authors recommend that primary malignancy be treated with targeted therapy.

show abstract

“…Importantly, in a recent large registry-based analysis, Morton and colleagues [4] noted an increasing incidence of treatment-related myeloid neoplasia (tMN) following treatment for esophagus cancer since the early 2000's. Although disease characteristics and clinical outcomes for tMN have been extensively studied in patients after treatment for breast cancer and lymphoma [5], only limited data exist for patients with a prior gastrointestinal malignancy, and all are confined to single case reports or small case series [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer

et al. 2019

View full text Add to dashboard Cite

Purpose: Luminal gastrointestinal tract cancers (LGC) are common malignancies, and many patients can achieve long-term responses with surgery, cytotoxic and/or targeted therapies, and radiation. The long-term follow-up for patients with durable disease control has not been fully characterized, including subsequent malignancies. Such cases have not been comprehensively described. Patients and methods:We identified patients evaluated for myeloid malignancies (MyM) who had a prior LGC at our institution over a 35-year period. Patient, disease, and treatment information was collected for analysis. Cytogenetic risk profiles were designated according to the Revised International Prognostic Scoring System for MDS and the European LeukemiaNet Guidelines for AML.Results: 66 patients were included in our cohort with 71 prior LGC diagnoses, including three patients with multiple LGCs. 31 cases were treated with surgery alone, and 37 patients received chemotherapy. The median age at diagnosis of MyM was 71.8 years (range, 36.2 to 90.5), with median duration between initiation of treatment of LGC and diagnosis MyM of 7.9 years (range 0.005-38.8). Intermediate or adverse (AML)/poor-very poor (MDS) cytogenetic risk was common, occurring in 43% of MDS patients and 100% of AML patients; deletion 5q was the most common cytogenetic abnormality overall. DNMT3A mutations were the most common molecular alteration (6 patients with 7 mutations).

show abstract

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer

Cited by 5 publications

References 20 publications

Secondary Acute Myeloid Leukemia: Pathogenesis and Treatment

Secondary Acute Myeloid Leukemia: Pathogenesis and Treatment

Genetic Pathway in the Pathogenesis of Therapy-Related Myeloid Neoplasms: A Literature Review

Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer

Contact Info

Product

Resources

About